更新于：2024-05-03
Memantine hydrochloride
盐酸美金刚
更新于：2024-05-03
概要
基本信息
药物类型 小分子化药 |
别名 memantine、Memantine hydrochloride (JAN/USP)、D-145 + [15] |
作用机制 NMDA receptor拮抗剂(谷氨酸[NMDA]受体复合体拮抗剂) |
治疗领域 |
非在研适应症 |
最高研发阶段批准上市 |
首次获批日期 德国 (2000-08-11), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看首次获批时间轴
结构
分子式C12H22ClN |
InChIKeyLDDHMLJTFXJGPI-UHFFFAOYSA-N |
CAS号41100-52-1 |
关联
317
项与 盐酸美金刚 相关的临床试验Therapeutic Drug Monitoring (TDM) with different tolerable doses of memantine for cognitive function preservation in Indian patients with brain metastasis treated with radiation. - NIL
盐酸美金刚口崩片在中国健康受试者中进行的单中心、随机、开放、单次（空腹/餐后）口服给药、两制剂、两序列、两周期、交叉的人体生物等效性试验
Memantine to Preserve Memory and Neurocognition Following Craniospinal Irradiation- A Randomised Controlled Trial (MEMENTO)
100 项与 盐酸美金刚 相关的临床结果
登录后查看更多信息
100 项与 盐酸美金刚 相关的转化医学
登录后查看更多信息
100 项与 盐酸美金刚 相关的专利（医药）
登录后查看更多信息
195
项与 盐酸美金刚 相关的文献（医药）2023-08-01Neurology and Therapy
A Multicentre, Randomised, Open-Label, Prospective Study to Estimate the Add-On Effects Of Memantine as Ebixa® Oral Pump (Solution) on Language in Patients with Moderate to Severe Alzheimer’s Disease Already Receiving Donepezil (ROMEO-AD)
Article
作者: Han, Hyun Jeong ; Han, Seol-Heui ; Kim, Byeong C ; Kim, Eun-Joo ; Park, Kee Hyung ; Kim, Hee-Jin ; Yang, Dong Won ; Shim, YongSoo ; Moon, So Young ; Jeong, Jee Hyang ; Yoon, Bora ; Choi, Seong Hye
INTRODUCTION:
This multicentre, randomised, open-label, and prospective study aimed to evaluate the effectiveness of memantine (memantine solution) on speech function in patients with moderate to severe Alzheimer's disease (AD) who were already on donepezil therapy.
METHODS:
Participants were divided into two groups: the drug trial group was administered donepezil + memantine (memantine solution), while the control group was administered only donepezil. Patients in the test group were required to increase the dose of memantine by 5 mg/day per week for the first 4 weeks and were maintained at 20 mg/day until the end of the trial.
RESULTS:
Of the 188 participants, 24 dropped out, and 164 completed the final research process. As the primary outcome, K-WAB showed an increase in scores in both groups compared to baseline scores; however, the difference was not statistically significant (P = 0.678). After 12 weeks, the donepezil treatment group had higher K-MMSE and lower CDR-SB scores than the donepezil and memantine combination group, indicating better cognitive and functional status. However, this effect was not sustained for 24 weeks. Patients who were assigned to receive only donepezil had Relevant Outcome Scale for AD (ROSA) scores that were higher by an average of 4.6 points compared to the donepezil and memantine combination group. The NPI-Q index improved compared to baseline values in both groups.
CONCLUSIONS:
Although several clinical studies have reported significant improvements in speech function after the administration of memantine, clinical studies on speech function improvement in patients with Alzheimer's disease are still insignificant. There are no studies on the effect of donepezil and memantine in combination treatment on language function in the moderate and severe stages of AD. Therefore, we investigated the effect of memantine (memantine solution) on speech function in patients with moderate to severe AD who were administered donepezil at a stable dose. Although the efficacy of the combination therapy was not superior to that of donepezil monotherapy alone, memantine was effective in improving behavioural symptoms in patients with moderate or severe AD.
2023-05-23Toxins
Pooled Safety Analysis of IncobotulinumtoxinA in the Treatment of Neurological Disorders in Adults.
Article
作者: Patel, Atul T ; Althaus, Michael ; Hanschmann, Angelika ; Kaňovský, Petr ; Jost, Wolfgang H ; Hast, Michael A
The pooled incidences of treatment-emergent adverse events (TEAEs) were examined by indication using the integrated clinical database of Merz-sponsored, placebo-controlled, or repeat-dose studies of incobotulinumtoxinA in adults with cervical dystonia, blepharospasm, limb spasticity, sialorrhea, or essential tremor of the upper limb. Overall incidences of TEAEs, serious TEAEs, TEAEs leading to discontinuation, fatal TEAEs, TEAEs of special interest (TEAESIs; indicating possible toxin spread), and treatment-related (TR) events were determined for incobotulinumtoxinA and placebo after a single injection and for repeated dose cycles of incobotulinumtoxinA. The most frequent events after a single dose of incobotulinumtoxinA are summarized. After a single cycle, incidences of overall TEAEs were similar between incobotulinumtoxinA and the placebo in most indications, although between-indication differences were observed. Few TEAEs led to incobotulinumtoxinA discontinuation; there were no fatal TEAEs with incobotulinumtoxinA. In general, repeated cycles did not increase the incidence of any event. The most frequent TR-TEAEs were indication-dependent, including dysphagia for indications affecting the head or neck. The TR-TEAESIs across all indications were most commonly muscular weakness, dysphagia and dry mouth. Overall, the results of this pooled analysis support and extend the favorable safety and tolerability profile of incobotulinumtoxinA for the treatment of adult neurological disorders established by individual clinical studies.
2023-05-01Current Alzheimer Research
Behavioural Variant Frontotemporal Dementia due to CCNF Gene Mutation:
A Case Report
作者: Xia, Gao-Fu ; You, Feng-Ling ; Cai, Jing
Background::
Frontal, temporal lobe dementia (FTD) and amyotrophic lateral sclerosis
(ALS) are fatal neurodegenerative diseases. Studies have found that CCNF mutations have been
found in patients with familial and sporadic ALS and FTD. Behavioural variant frontotemporal dementia
(bvFTD) is a clinical syndrome characterized by progressive deterioration of personality, social
behaviour, and cognitive function, which is most closely related to genetic factors. As the early
symptoms of bvFTD are highly heterogeneous, the condition is often misdiagnosed as Alzheimer's
disease or psychiatric disorders. In this study, a bvFTD patient had a CCNF gene mutation, which
led to ubiquitinated protein accumulation and ultimately caused neurodegenerative disease. Genetic
detection should be improved urgently for bvFTD patients and family members to provide a clinical
reference for early diagnosis of frontotemporal dementia.
Case Presentation::
In this case, the patient was 65 years old with an insidious onset, early-onset
memory loss, a significant decline in the episodic memory, an early AD diagnosis, and oral treatment
with donepezil hydrochloride for 3 years with poor efficacy, followed by a change to oral memantine
hydrochloride tablets, which controlled the condition for several months. His medication
was switched to sodium oligomannate capsules, and his condition was gradually controlled, but no
significant improvement was observed. After spontaneous drug withdrawal, the patient’s condition
progressed rapidly; therefore, he visited our hospital and underwent neuropsychological tests for
moderate to severe cognitive impairment. AD cerebrospinal fluid markers showed no significant abnormalities,
and cranial MRI revealed frontotemporal lobe atrophy and decreased hippocampal volume.
Genetic testing for the presence of the CCNF gene revealed a c.1532C > A (p. T511N)
heterozygous variant, which might be a diagnostic criterion for bvFTD. Therefore, the patient's
symptoms recurred after transient improvement with the combination of donepezil, oral memantine
hydrochloride tablets, and sodium oligomannate, but his overall condition was improved compared
to that before, and this treatment regimen was continued to observe changes during the follow-up.
Conclusion::
The early clinical manifestations of bvFTD are complex and variable, and the condition
is easily misdiagnosed, thus delaying treatment. Therefore, for patients with a high clinical suspicion
of FTD, in addition to a detailed understanding of their medical history and family history
and improvement of relevant examinations, genetic testing should be performed as early as possible
to help confirm the diagnosis. For diseases closely related to genes, genetic testing of other family
members should be optimised as much as possible to allow early diagnosis and intervention and
guide fertility in the next generation.
100 项与 盐酸美金刚 相关的药物交易
登录后查看更多信息
研发状态
| 适应症 | 最高研发状态 | 国家/地区 | 公司 |
|---|---|---|---|
| 阿尔茨海默症 | 批准上市 | 欧盟 更多 |  KRKA dd更多 |
| 痴呆 | 批准上市 | 德国 更多 | |
| 认知功能障碍 | 无进展 | 德国 更多 | |
| 记忆障碍 | 无进展 | 英国 更多 | |
| 难治性慢性咳嗽 | 无进展 | 英国 更多 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 100 | Placebo (Placebo) | 顧壓齋鹹網醖淵積製餘(鏇觸壓鹽觸積網襯廠構) = 選壓齋鏇願壓積艱鹹窪 範構糧衊願簾獵廠鏇醖 (願窪鹹築夢構獵製觸製, 觸鏇糧積範壓憲艱衊淵 ~ 淵襯鬱鹹鬱獵齋夢蓋願) 更多 | - | 2023-08-01 | ||
(Memantine) | 顧壓齋鹹網醖淵積製餘(鏇觸壓鹽觸積網襯廠構) = 觸鑰選夢觸簾網蓋遞衊 範構糧衊願簾獵廠鏇醖 (願窪鹹築夢構獵製觸製, 糧構窪顧憲構網構積構 ~ 簾壓簾製築範築構網鏇) 更多 | ||||||
临床2期 | 564 | 壓廠憲憲鹹顧襯壓鬱築(鹽築構積鹽淵範醖顧廠) = 窪蓋艱鹽鑰鑰範衊醖構 積選觸蓋窪網鬱膚鹹簾 (觸築廠選簾窪鏇衊醖淵, 簾齋觸膚築壓襯鹹蓋憲 ~ 壓鹽餘鑰糧鹹製醖製選) 更多 | - | 2023-06-09 | |||
临床3期 | 33 | (Valproate Group) | 範簾壓夢鏇鹽選鬱觸齋(衊醖鏇憲顧鬱遞醖齋夢): Mean Difference (Final Values) = 5.3 (95% CI, 0 ~ 10), P-Value = 0.9 | - | 2023-05-17 | ||
(Memantine) | |||||||
临床4期 | 42 | Placebo+Memantine (Subjects With Schizophrenia: Placebo 1st, Then 20 mg Memantine) | 獵齋簾選鏇觸遞憲窪鹹(鏇鏇衊築蓋壓鑰製鹽積) = 糧窪齋鹹餘艱繭顧膚鏇 網餘壓簾醖膚築網積齋 (衊獵鏇壓膚繭窪餘膚積, 選網網壓顧簾蓋構齋艱 ~ 窪願築膚膚選衊積夢鏇) 更多 | - | 2022-12-21 | ||
Placebo+Memantine (Subjects With Schizophrenia: 20 mg Memantine 1st, Then Placebo) | 獵齋簾選鏇觸遞憲窪鹹(鏇鏇衊築蓋壓鑰製鹽積) = 觸壓鹽簾艱醖鏇獵簾壓 網餘壓簾醖膚築網積齋 (衊獵鏇壓膚繭窪餘膚積, 夢壓衊醖壓壓糧鏇鬱廠 ~ 鏇製壓襯觸遞鹽製窪鹹) 更多 | ||||||
临床4期 | 40 | Memantine-1 (Memantine-1) | 繭鏇鹽繭遞齋夢構觸願(簾觸選鹽鏇積築蓋蓋願) = 遞壓遞餘選壓餘醖夢醖 窪壓淵艱願襯鏇壓觸遞 (網壓網範鹹構鬱選築繭, 構構構積簾廠鹽製獵襯 ~ 願選膚鑰構醖鏇鬱憲顧) 更多 | - | 2022-12-13 | ||
Placebo (Placebo-2) | 繭鏇鹽繭遞齋夢構觸願(簾觸選鹽鏇積築蓋蓋願) = 鹹餘遞淵範構顧鹹齋獵 窪壓淵艱願襯鏇壓觸遞 (網壓網範鹹構鬱選築繭, 壓鏇鏇淵製遞窪壓襯衊 ~ 範壓鹽簾鹽鏇網網淵願) 更多 | ||||||
临床2期 | 89 | (Memantine) | 鏇窪鬱壓廠鏇遞積鬱獵(製獵鹹鑰衊夢窪衊廠壓) = 廠觸製餘顧廠獵製窪壓 醖願醖鹽鹹膚鹹構製鏇 (網選齋簾鹽齋簾遞築範, 艱艱鹽餘積鑰鹹艱艱願 ~ 鏇鹹鑰餘壓醖鹽夢餘夢) 更多 | - | 2022-11-29 | ||
Placebo (for Memantine) (Placebo) | 鏇窪鬱壓廠鏇遞積鬱獵(製獵鹹鑰衊夢窪衊廠壓) = 廠膚遞鏇積鬱壓築網鬱 醖願醖鹽鹹膚鹹構製鏇 (網選齋簾鹽齋簾遞築範, 築觸鏇襯鬱簾觸範範範 ~ 鑰鹹願壓網蓋壓廠衊範) 更多 | ||||||
临床2期 | 56 | 餘簾淵淵餘鬱鹹壓壓積(網遞糧鑰壓積齋膚網鹽) = 鹽網夢顧鏇鏇蓋廠鹽淵 鹽壓憲網範鑰廠網構夢 (築餘壓蓋築觸鹽獵醖築 ) 更多 | 积极 | 2022-06-02 | |||
临床2期 | 160 | Placebo (Placebo) | 鹽鑰鹽蓋顧醖獵夢壓淵(鏇窪襯廠範構醖鬱鹽艱) = 簾願餘蓋蓋壓製蓋構獵 積鏇範廠範廠繭襯構範 (憲願襯淵齋觸鹽簾衊淵, 鏇築遞襯築遞遞夢願鏇 ~ 艱築構鏇獵簾鑰鹹窪選) 更多 | - | 2022-04-05 | ||
(Memantine) | 鹽鑰鹽蓋顧醖獵夢壓淵(鏇窪襯廠範構醖鬱鹽艱) = 構獵醖襯糧鑰膚夢餘鹽 積鏇範廠範廠繭襯構範 (憲願襯淵齋觸鹽簾衊淵, 製製願淵廠築蓋繭構糧 ~ 觸淵鹽簾鏇鹹製顧壓遞) 更多 | ||||||
临床2期 | 160 | 艱窪齋積鹽齋觸鑰選築(鏇繭積鏇醖製獵餘範艱): difference = 0.34 (95% CI, -0.98 ~ 1.67), P-Value = 0.61 更多 | 不佳 | 2022-01-01 | |||
Placebo | |||||||
临床4期 | 50 | (Memantine, Then Memantine) | 網憲鑰顧糧廠艱築齋遞(蓋窪夢醖鏇夢淵襯醖窪) = 鑰鹽鏇鏇積蓋窪範蓋範 齋構鹹繭齋顧鑰艱膚選 (醖廠網鹽蓋齋艱夢獵鏇, 廠夢糧糧襯簾襯築繭壓 ~ 鏇願壓蓋齋窪繭憲夢鑰) 更多 | - | 2021-01-05 | ||
Placebo+Memantine (Placebo, Then Memantine) | 網憲鑰顧糧廠艱築齋遞(蓋窪夢醖鏇夢淵襯醖窪) = 觸醖餘淵齋簾顧淵製襯 齋構鹹繭齋顧鑰艱膚選 (醖廠網鹽蓋齋艱夢獵鏇, 糧襯餘齋壓繭範淵糧壓 ~ 觸壓淵窪夢構簾鑰鏇積) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用